Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

About this update from Kyverna Therapeutics, Inc.

[{"type":"image","alt":"Kyverna Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Kyverna Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/6f9f28e393a47bcb20d3d0e1f187b2f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NgRte8yTQVY2_NCia6rH2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6f9f28e393a47bcb20d3d0e1f187b2f0","width":300,"height":120}},"lazy":false},{"type":"text","content":"EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the following upcoming conferences:","length":344,"tagName":"p"},{"type":"text","content":"2025 Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, September 3rd, 2025Time: 11:00 a.m. ET","length":117,"tagName":"p"},{"type":"text","content":"Morgan Stanley 23rd Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Monday, September 8th, 2025Time: 4:05 p.m. ET","length":130,"tagName":"p"},{"type":"text","content":"H.C. Wainwright 27th Annual Global Investment ConferenceFormat: Fireside Chat Date: Tuesday, September 9th, 2025Time: 11:00 a.m. ET","length":134,"tagName":"p"},{"type":"text","content":"Live webcasts of the presentations may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. Archived replays of all events will be available on the website for approximately 90 days following the conference.","length":236,"tagName":"p"},{"type":"text","content":"About Kyverna Therapeutics ","length":26,"tagName":"p"},{"type":"text","content":"Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis.  The Company is also harnessing other KYSA trials and investig...

More updates from Kyverna Therapeutics, Inc.